NCT03525262 - Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions

Prostate Cancer Adenocarcinoma

Interventions

RADIATION

30Gy (Gray) planning target volume (PTV)

PTV1\_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).

Trial Locations (8)

11794

Stony Brook University Cancer Center, Stony Brook

19104

Penn Medicine Radiation Oncology, Philadelphia

44195

Cleveland Clinic, Cleveland

48109

University of Michigan- Michigan Medicine, Ann Arbor

75235

UT Southwestern Cancer Center, Dallas

80045

University of Colorado Hospital, Aurora

80907

Penrose Hospital, Colorado Springs

94143

UCSF ( Department of Radiation Oncology University of California San Francisco), San Francisco